DTI-Tech Launches IFDREAM, a Next-Generation Platform for Drug Target Identification and Rapid Resistance Modeling

Swiss biotech introduces integrated technology designed to accelerate oncology drug development and predict therapeutic resistance earlier in preclinical stages

Bellinzona, Switzerland – 23 June 2026 – DTI-Tech, a Swiss biotech company focused on innovative drug target identification and resistance modeling technologies, today announced the launch of **IFDREAM (Integrate Functional Drug-REsponse mApping systeM)**, a proprietary platform designed to help pharmaceutical and biotechnology companies accelerate oncology drug development and better predict resistance mechanisms during preclinical research.

IFDREAM combines two complementary technologies into a single integrated workflow: a label-free drug target identification method and a rapid system for generating drug-resistant cancer models. Together, these capabilities enable researchers to monitor target engagement, pathway modulation, and resistance evolution over time, providing a more comprehensive understanding of the mechanism of action of novel therapeutic compounds.

“Understanding how cancer cells adapt to therapeutic pressure is one of the most critical challenges in oncology drug development,” said Eugenio Gaudio, co-founder of DTI-Tech. “With IFDREAM, we provide pharma and biotech companies with an integrated platform capable of identifying drug targets while simultaneously modeling resistance evolution in real time. This allows earlier de-risking of drug candidates and supports the development of more effective therapeutic strategies.”

Current drug target identification technologies often require drug labeling, linker modifications, or indirect approaches that may alter the native interaction between small molecules and proteins. DTI-Tech’s proprietary method preserves both compounds and protein targets in their native state, enabling unbiased identification of drug-protein interactions without chemical modification of the molecule under investigation.

In parallel, DTI-Tech has developed a proprietary booster-medium and co-culture system that enables the rapid generation of resistant cancer cell models under continuous drug exposure. By integrating resistance evolution with target engagement analysis, IFDREAM provides insights into primary and secondary targets, pathway adaptations, and potential off-target effects emerging during treatment.

According to the company, no current contract research organization (CRO) offers an integrated solution combining rapid resistance modeling with drug target identification and longitudinal pathway analysis.

“IFDREAM was developed to address a growing unmet need in precision oncology research,” said Francesco Paduano, co-founder of DTI-Tech. “Drug developers increasingly need predictive preclinical systems capable not only of identifying mechanisms of action, but also anticipating resistance mechanisms likely to emerge in patients. Our platform was specifically designed to bridge this gap.”

The platform is intended for biotech and pharmaceutical companies developing novel drug-like small molecules, particularly in oncology indications where acquired therapeutic resistance remains a major barrier to long-term efficacy.

DTI-Tech believes the integrated approach offered by IFDREAM has the potential to reduce development risks, improve translational relevance, and support the design of optimized combination therapies capable of overcoming resistance before clinical failure occurs.

About DTI-Tech

DTI-Tech is a Swiss biotechnology company focused on innovative drug target identification and rapid generation of resistant disease models. The company develops integrated technologies designed to help pharmaceutical and biotech companies de-risk drug development by identifying therapeutic targets and predicting resistance mechanisms earlier in the preclinical process.

For more information, visit www.dtitech.ch



Figure 1. IFDREAM platform. Each cancer model will undergo treatment with increased concentration of a single selected compound with the aim to generate a drug resistant model. Cells will receive two treatments per week and for 4 weeks. At the end of each week the model will by investingated through the DTI method for the detection of primary and secondary targets, pathways modulations and mechanism of action of each compound by mass spectrometry analysis.